Kinome activity profiling to gain more insights into the adaptive resistance mechanism of rhabdomyosarcoma (RMS) cell lines towards FGFR4 inhibitor
Ended Purchase Order Awarded
- Contract number
- 75N91022P00264
- Awardee
-
Pamgene International B.V. UEI DVBJJ8WMJ3M3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,950
Award facts
- Contract value 100% obligated
- $14,950.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
Award details come from SAM.gov/FPDS.
Quick answers
Who was awarded contract 75N91022P00264?
75N91022P00264 was awarded to Pamgene International B.V. by National Cancer Institute (National Institutes of Health) on February 14, 2022.
How much is contract 75N91022P00264 worth?
The government has obligated $14,950 on 75N91022P00264.
Was contract 75N91022P00264 competed?
The extent of competition for 75N91022P00264 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award